Dabigatran
- Generic Name
- Dabigatran
- Brand Names
- Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N7O3
- CAS Number
- 211914-51-1
- Unique Ingredient Identifier
- I0VM4M70GC
- Background
Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 5350
- Registration Number
- NCT04735523
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
- Conditions
- Myocardial InfarctionMyocardial IschemiaAtrial FibrillationCoronary Artery Disease
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Zuyderland Medisch Centrum
- Target Recruit Count
- 1000
- Registration Number
- NCT04688723
- Locations
- 🇳🇱
Zuyderland MC, Heerlen, Limburg, Netherlands
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
- Conditions
- Anticoagulant-induced BleedingSurgery, OralHemorrhageOral Surgical ProceduresPostoperative ComplicationsAnticoagulants Causing Adverse Effects in Therapeutic Use
- Interventions
- Procedure: Type of surgery
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Malmö University
- Target Recruit Count
- 216
- Registration Number
- NCT04662515
- Locations
- 🇸🇪
Skåne University Hospital, Helsingborg, Sweden
🇸🇪Department of Oral and Maxillofacial Surgery and Oral Medicine, Faculty of Odontology, Malmö University, Malmö, Sweden
Anticoagulation in Patients With Venous Thromboembolism and Cancer
- Conditions
- NeoplasmsEmbolism
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT04618913
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Replication of the RELY Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 78140
- Registration Number
- NCT04593043
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 898
- Registration Number
- NCT04532528
- Locations
- 🇨🇳
Buddhist Tzu Chi General Hospital, Hualien, Taiwan
🇨🇳National Taiwan University Hospital-Hsin-Chu Branch, Hsinchu, Taiwan
🇨🇳Pingtung Christian Hospital, Pingtung, Taiwan
Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
- Conditions
- RSV Infection
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 89
- Registration Number
- NCT04498741
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
- Conditions
- Heavy Menstrual Bleeding
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Cardioangiologisches Centrum Bethanien
- Target Recruit Count
- 84
- Registration Number
- NCT04477837
- Locations
- 🇩🇪
Cardioangiology Center Bethanien (CCB), Frankfurt am Main, Germany
A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants
- Conditions
- Healthy SubjectsPharmacokineticsQuizartinibDrug-drug Interaction
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04459585
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis
- Conditions
- Liver CirrhosisPortal Vein Thrombosis
- Interventions
- Other: Placebo
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 84
- Registration Number
- NCT04433481
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, Delhi, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.